Non-insulin Diabetes Therapeutics Market by Type, Distribution Channel and Geography - Forecast and Analysis 2023-2027
| Published: May 2023 | Pages: 172 | SKU: IRTNTR70604 |
The non-insulin diabetes therapeutics market size is estimated to grow at a CAGR of 10.82% between 2022 and 2027. The market size is forecast to increase by USD 31,251.55 million. The growth of the market depends on several factors, including the increasing number of people with type 2 diabetes, the growing prevalence of diabetes among people aged 6-19 and 35-50, and recent product approvals.
This non-insulin diabetes therapeutics market report extensively covers market segmentation by type (DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others), distribution channel (offline and online), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
What will be the Size of the Non-insulin Diabetes Therapeutics Market During the Forecast Period?
To learn more about this report, View Report Sample
Non-insulin Diabetes Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape
The increasing number of people with type 2 diabetes is notably driving the market growth, although factors such as concerns about safety may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Non-insulin Diabetes Therapeutics Market Driver
An increasing number of people with type 2 diabetes is the key factor driving the growth of the global non-insulin diabetes therapeutics market. Type 2 diabetes is caused by the ineffective use of insulin produced by the body. It is the most common form of diabetes worldwide. Obesity and lack of exercise are the most common causes of type 2 diabetes. Type 2 diabetes is caused by hyperglycemia and metabolic changes due to abnormal insulin secretion and action. Until the early 2000s, the disease was common only in adults. However, the prevalence of type 2 diabetes in children is increasing.
The early diagnosis of type 2 diabetes is often a challenge due to the generic symptoms associated with the disease. Hence, once the disease is diagnosed, it is essential to provide advanced medications. Different antihyperglycemic drugs are used alone or in combination with other drugs, such as insulin, to treat type 2 diabetes. The initial steps of treatment include weight loss plans, lifestyle changes, and the administration of metformin. The ADA and the European Association for the Study of Diabetes (EASD) recommend a patient-specific treatment approach to enhance glycemic control to treat type 2 diabetes. This is to avoid weight gain and hypoglycemia. Hence, the increasing number of people with type 2 diabetes will drive the growth of the global non-insulin diabetes therapeutics market during the forecast period.
Significant Non-insulin Diabetes Therapeutics Market Trends
Innovations in therapies are the primary trend shaping the global non-insulin diabetes therapeutics market growth. Several vendors are introducing advanced therapies to treat diabetes. Incretins are GLP-1 and glucose-dependent insulinotropic polypeptides (GIP), which are secreted by the GI tract in response to food intake. Both GLP-1 and GIP stimulate the beta cells of the pancreas, which contribute 60% of the insulin secreted after a meal. Type 2 diabetes reduces the secretion of GLP-1 and reduces responsiveness to GIP. The benefits of incretin hormones on glycemic control include enhanced satiety, decreased GI motility, increased glucose-dependent insulin secretion, reduced glucagon secretion, and decreased hepatic glucose release. Two incretin-based drug classes are used to treat people with type 2 diabetes. These include oral DPP4 inhibitors and GLP-1 receptor agonists.
The pathophysiology of type 2 diabetes involves at least seven organs and tissues, which include the brain, liver, pancreas, intestines, kidneys, fat, and muscles. No single medication addresses all seven organs and tissues. Most people require more than one medication to treat the disease. Hence, drugs with unique and complementary MoA are required. Therapeutics such as DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, colesevelam, and bromocriptine QR provide therapeutic options with novel MoA. They also prevent weight gain and reduce the risk of hypoglycemia. Though all medications are not appropriate for all people, they offer healthcare providers options to individualize treatments and optimize care for patients. Hence, the market is expected to grow during the forecast period.
Major Non-insulin Diabetes Therapeutics Market Challenge
Concerns about safety are a major challenge to the growth of the global non-insulin diabetes therapeutics market. Several non-insulin diabetes drugs are currently under review by the US FDA due to safety concerns. For example, in 2017, the U.S. Food and Drug Administration added a boxed warning to the label of Janssen type 2 diabetes medication because it increases the risk of leg and foot amputations. That's why the company's type 2 diabetes medications like Invokana, Invokamet, and Invokamet XR should include a risk statement in the box next to the canagliflozin drug label.
In 2015, the US FDA also revised the labels of SGLT2 inhibitors to include warnings about the risk of high levels of acid in the blood and the possibility of severe urinary tract infections (UTIs). Such initiatives are increasing awareness about the safety of certain drugs. However, they are a challenge for the growth of the global non-insulin diabetes therapeutics market as vendors must make significant investments in R&D to develop safe drugs. Hence, safety concerns may hamper the growth of the market during the forecast period.
Key Non-insulin Diabetes Therapeutics Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Non-insulin Diabetes Therapeutics Market Customer Landscape
Who are the Major Non-insulin Diabetes Therapeutics Market Vendors?
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories: The company offers non insulin diabetes therapeutics solutions such as Abbotts Freestyle libre system significantly reduces HBA1C levels in people with type 2 diabetes.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
- AstraZeneca PLC
- Better Therapeutics Inc.
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck KGaA
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- The Cleveland Clinic Foundation
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
What is the Fastest-Growing Segment in the Non-insulin Diabetes Therapeutics Market?
The market share growth by the DPP4 inhibitors segment will be significant during the forecast period. DPP4 inhibitors are therapeutics that reduce high blood glucose levels. They are widely used to treat type 2 diabetes. DPP4 inhibitors improve blood glucose control and reduce fasting and postprandial blood glucose levels without causing weight gain. The changes of hypoglycemia are low when using DPP4 inhibitors unless they are combined with other therapies that cause hypoglycemia.
Get a glance at the market contribution of various segments View the PDF Sample
The DPP4 inhibitors segment was valued at USD 11,810.09 million in 2017 and continued to grow until 2021. DPP4 inhibitors block the action of DPP4, an enzyme that destroys incretin. As incretin helps the body produce more insulin when needed and reduces the amount of glucose produced by the body when not required, its destruction could cause type 2 diabetes. These hormones are released throughout the day, and their levels increase during the consumption of food. Therefore, DPP4 inhibitors are required to stabilize type 2 diabetes. Hence, their adoption is high across the world. Such factors will increase segment growth during the forecast period.
Which are the Key Regions for the Non-insulin Diabetes Therapeutics Market?
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Several vendors offer non-insulin diabetes therapeutics in North America, which is increasing awareness and the availability of non-insulin diabetes therapeutics in the region. The vendors are focusing on product development and clinical trials. Hence, the availability of advanced therapeutics and delivery techniques is improving in the region. However, several stringent regulations have been implemented in the region. For instance, in 2008, the US FDA published guidance for the industry, which recommended that new drug applications (NDAs) for diabetes should include evidence that they do not increase the risk of cardiovascular events. Hence, vendors must make significant investments in R&D to develop therapeutics that are safe.
In 2020, the outbreak of COVID-19 affected the economies of various countries in North America, especially the US. However, the initiation of large-scale vaccination drives led to the lifting of restrictions in 2021. This has resulted in the resumption of normal treatments, which has increased the demand for non-insulin diabetes therapeutics in the region. Such factors are expected to drive the growth of the regional market during the forecast period.
Segment Overview
The non-insulin diabetes therapeutics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
- Type Outlook (USD Million, 2017 - 2027)
- DPP4 inhibitors
- GLP-1 receptor agonists
- SGLT2 inhibitors
- Others
- Distribution Channel Outlook (USD Million, 2017 - 2027)
- Offline
- Online
- Region Outlook (USD Million, 2017 - 2027)
- North America
- The U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- ROW
- Argentina
- Australia
- Rest of the world
- North America
Parent Market Analysis
Technavio categorizes the global non-insulin diabetes therapeutics market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
|
Non-insulin Diabetes Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
172 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.82% |
|
Market growth 2023-2027 |
USD 31,251.55 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
10.02 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key countries |
US, Germany, UK, China, and India |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, AstraZeneca PLC, Better Therapeutics Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and The Cleveland Clinic Foundation |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Non-insulin Diabetes Therapeutics Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the market between 2023 and 2027
- Precise estimation of the market size and its contribution of the market in focus to the parent market
- Accurate predictions about upcoming trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of market vendors
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global non-insulin diabetes therapeutics market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on global non-insulin diabetes therapeutics market 2017 - 2021 ($ million)
- 4.2 Type Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million)
- 4.3 Distribution Channel Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Type
- 6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
- 6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type
- 6.3 DPP4 inhibitors - Market size and forecast 2022-2027
- Exhibit 34: Chart on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on DPP4 inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on DPP4 inhibitors - Year-over-year growth 2022-2027 (%)
- 6.4 GLP-1 receptor agonists - Market size and forecast 2022-2027
- Exhibit 38: Chart on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
- 6.5 SGLT2 inhibitors - Market size and forecast 2022-2027
- Exhibit 42: Chart on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on SGLT2 inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on SGLT2 inhibitors - Year-over-year growth 2022-2027 (%)
- 6.6 Others - Market size and forecast 2022-2027
- Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
- Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
- 6.7 Market opportunity by Type
- Exhibit 50: Market opportunity by Type ($ million)
- Exhibit 51: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Exhibit 52: Chart on Distribution Channel - Market share 2022-2027 (%)
- Exhibit 53: Data Table on Distribution Channel - Market share 2022-2027 (%)
- 7.2 Comparison by Distribution Channel
- Exhibit 54: Chart on Comparison by Distribution Channel
- Exhibit 55: Data Table on Comparison by Distribution Channel
- 7.3 Offline - Market size and forecast 2022-2027
- Exhibit 56: Chart on Offline - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Offline - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Offline - Year-over-year growth 2022-2027 (%)
- 7.4 Online - Market size and forecast 2022-2027
- Exhibit 60: Chart on Online - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Online - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Online - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Online - Year-over-year growth 2022-2027 (%)
- 7.5 Market opportunity by Distribution Channel
- Exhibit 64: Market opportunity by Distribution Channel ($ million)
- Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 Germany - Market size and forecast 2022-2027
- Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.9 China - Market size and forecast 2022-2027
- Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.10 UK - Market size and forecast 2022-2027
- Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.11 India - Market size and forecast 2022-2027
- Exhibit 103: Chart on India - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on India - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on India - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on India - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 112: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 113: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification
- 12.3 Abbott Laboratories
- Exhibit 115: Abbott Laboratories - Overview
- Exhibit 116: Abbott Laboratories - Business segments
- Exhibit 117: Abbott Laboratories - Key news
- Exhibit 118: Abbott Laboratories - Key offerings
- Exhibit 119: Abbott Laboratories - Segment focus
- 12.4 AstraZeneca PLC
- Exhibit 120: AstraZeneca PLC - Overview
- Exhibit 121: AstraZeneca PLC - Product / Service
- Exhibit 122: AstraZeneca PLC - Key news
- Exhibit 123: AstraZeneca PLC - Key offerings
- 12.5 Better Therapeutics Inc.
- Exhibit 124: Better Therapeutics Inc. - Overview
- Exhibit 125: Better Therapeutics Inc. - Product / Service
- Exhibit 126: Better Therapeutics Inc. - Key news
- Exhibit 127: Better Therapeutics Inc. - Key offerings
- 12.6 Boehringer Ingelheim International GmbH
- Exhibit 128: Boehringer Ingelheim International GmbH - Overview
- Exhibit 129: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 130: Boehringer Ingelheim International GmbH - Key news
- Exhibit 131: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 132: Boehringer Ingelheim International GmbH - Segment focus
- 12.7 Eli Lilly and Co.
- Exhibit 133: Eli Lilly and Co. - Overview
- Exhibit 134: Eli Lilly and Co. - Product / Service
- Exhibit 135: Eli Lilly and Co. - Key news
- Exhibit 136: Eli Lilly and Co. - Key offerings
- 12.8 F. Hoffmann La Roche Ltd.
- Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus
- 12.9 GlaxoSmithKline Plc
- Exhibit 142: GlaxoSmithKline Plc - Overview
- Exhibit 143: GlaxoSmithKline Plc - Business segments
- Exhibit 144: GlaxoSmithKline Plc - Key news
- Exhibit 145: GlaxoSmithKline Plc - Key offerings
- Exhibit 146: GlaxoSmithKline Plc - Segment focus
- 12.10 Johnson and Johnson Services Inc.
- Exhibit 147: Johnson and Johnson Services Inc. - Overview
- Exhibit 148: Johnson and Johnson Services Inc. - Business segments
- Exhibit 149: Johnson and Johnson Services Inc. - Key news
- Exhibit 150: Johnson and Johnson Services Inc. - Key offerings
- Exhibit 151: Johnson and Johnson Services Inc. - Segment focus
- 12.11 Merck KGaA
- Exhibit 152: Merck KGaA - Overview
- Exhibit 153: Merck KGaA - Business segments
- Exhibit 154: Merck KGaA - Key news
- Exhibit 155: Merck KGaA - Key offerings
- Exhibit 156: Merck KGaA - Segment focus
- 12.12 Novartis AG
- Exhibit 157: Novartis AG - Overview
- Exhibit 158: Novartis AG - Business segments
- Exhibit 159: Novartis AG - Key offerings
- Exhibit 160: Novartis AG - Segment focus
- 12.13 Novo Nordisk AS
- Exhibit 161: Novo Nordisk AS - Overview
- Exhibit 162: Novo Nordisk AS - Business segments
- Exhibit 163: Novo Nordisk AS - Key offerings
- Exhibit 164: Novo Nordisk AS - Segment focus
- 12.14 Pfizer Inc.
- Exhibit 165: Pfizer Inc. - Overview
- Exhibit 166: Pfizer Inc. - Product / Service
- Exhibit 167: Pfizer Inc. - Key news
- Exhibit 168: Pfizer Inc. - Key offerings
- 12.15 Sanofi SA
- Exhibit 169: Sanofi SA - Overview
- Exhibit 170: Sanofi SA - Business segments
- Exhibit 171: Sanofi SA - Key news
- Exhibit 172: Sanofi SA - Key offerings
- Exhibit 173: Sanofi SA - Segment focus
- 12.16 Takeda Pharmaceutical Co. Ltd.
- Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 176: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 177: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 12.17 The Cleveland Clinic Foundation
- Exhibit 178: The Cleveland Clinic Foundation - Overview
- Exhibit 179: The Cleveland Clinic Foundation - Product / Service
- Exhibit 180: The Cleveland Clinic Foundation - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 181: Inclusions checklist
- Exhibit 182: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 183: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 184: Research methodology
- Exhibit 185: Validation techniques employed for market sizing
- Exhibit 186: Information sources
- 13.5 List of abbreviations
- Exhibit 187: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
non-insulin diabetes therapeutics market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis